Skip to content

#罕见病

Today 0 items
Oct 15Thu
  1. fda.gov53

    FDA Rare Disease Innovation Hub

    The FDA Rare Disease Innovation Hub released its Strategic Agenda on February 2, 2026, setting out its goals and priorities for the coming year for the rare disease community. The Hub, co-led by the directors of CBER, CDER and CDRH with the Oncology Center of Excellence and Office of Orphan Products Development, will focus on products for smaller populations and diseases with variable, poorly understood natural history. It has scheduled public meetings for October 16 and October 28, 2026.

  2. fda.gov51

    FDA Rare Disease Framework Initiative Public Meeting - 10/28/2026

    The FDA, with the Reagan-Udall Foundation for the FDA, will hold a hybrid public meeting on October 28, 2026, from 1:00 p.m. to 5:00 p.m. ET at the FDA White Oak Campus in Silver Spring, Maryland, and via Zoom. The meeting seeks input from patients, advocates, sponsors and others on the FDA's Rare Disease Framework Initiative, which aims to build a fit-for-purpose approach to rare disease drug development in small patient populations. Public remarks will inform the agency's work on the Framework, with input sought on fit-for-purpose review, regulatory predictability, external engagement and CMC considerations.

  3. fda.gov62

    FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development

    The FDA launched the Rare Disease Framework Initiative to build a fit-for-purpose framework for developing drugs and biologics for rare diseases, outlined in a new white paper dated October 14, 2026. The initiative, led by the Rare Disease Innovation Hub with the Commissioner's office, CBER and CDER, will tailor regulatory requirements to small patient populations, with only about 5% of rare conditions having an FDA-approved treatment. A public meeting on October 28 at the White Oak campus, facilitated by the Reagan-Udall Foundation, opens a feedback process that will inform new guidance, regulation revisions, training and organizational changes.

  4. fda.gov63

    Rare Disease Framework

    The FDA, with the Reagan-Udall Foundation for the FDA, will hold a hybrid public meeting on October 28, 2026, to gather input on its Rare Disease Framework Initiative, which aims to reimagine the agency's approach to rare disease drug development and review. The framework would tailor regulatory advice and decision-making to the evidence reasonably attainable for each disease, embed the patient voice at defined milestones, leverage external expertise, and apply risk-based approaches to manufacturing review and inspections. Changes could come through regulations, guidance documents and internal processes; FDA set out its aims in a white paper released October 14, 2026.

    Why it matters: FDA's rare disease development and review overhaul could change regulatory expectations for sponsors of orphan drugs.

Oct 7Wed
  1. fda.gov40

    Rare Disease Drug Approvals

    FDA's CDER lists recent rare disease drug approvals on its Accelerating Rare Disease Cures Program page. In 2026 alone these include Camzyos for an inherited heart condition in children, Emcitate for MCT8 deficiency, Isembyld for muscle loss in spinal muscular atrophy, and Zanvastro for Alexander Disease, among others. The list spans 2021 to 2026 and links to the underlying FDA news releases.

Oct 6Tue
  1. fda.gov40

    Rare Disease News & Events

    The FDA's ARC Program reviewed its 2025 rare disease work, reporting more than 30 public speaking engagements, 57-plus workshops, consults or meetings supporting rare disease drug development, and 45,000 rare disease news subscribers served. CDER approved 46 novel drugs in 2025, with 32 approved first in the U.S. and 23 carrying orphan drug designation. In FY25 the Office of Orphan Products Development granted 450 of 657 original orphan-drug designation requests, and public workshops on rare disease data sharing and neonatal product development are scheduled or archived for 2026.

Sep 29Tue
  1. fda.gov65

    FDA Approves First Treatment for MCT8 Deficiency

    The FDA approved Emcitate (tiratricol) oral suspension, from Egetis Therapeutics US Inc., for peripheral thyrotoxicosis in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. It is the first FDA-approved therapy for the rare genetic disease, which mainly affects males. Evidence came from a randomized placebo-controlled trial (NCT05579327) and a longer-term open-label study spanning infants to adults. The once-daily liquid can be given by mouth or feeding tube.

    Why it matters: First FDA-approved therapy for MCT8 deficiency, a rare genetic disease with no prior treatment option.

Sep 18Fri
  1. ema.europa.eu40

    Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026

    The EMA's CHMP recommended 12 new medicines for approval at its September 2026 meeting, including Frehemgo (denecimig) for bleeding prophylaxis in haemophilia A, Gevalka (ensartinib) for ALK-positive advanced non-small cell lung cancer, and Povofortay (povorcitinib), the first oral daily treatment for adults with hidradenitis suppurativa refractory or intolerant to anti-TNF therapy. Two initial marketing authorisation applications were withdrawn, Isembyld for 5q spinal muscular atrophy and Zinmyleo for chemotherapy-induced myelosuppression. Re-examinations of negative opinions for Kemsu, Meplyffa and Qezzaqar will follow once grounds are received.

  2. fda.gov70

    FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A

    The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time intravenous AAV9 gene therapy from Ultragenyx Pharmaceutical, as the first treatment for pediatric patients with mucopolysaccharidosis type IIIA, or Sanfilippo syndrome type A. In an open-label, single-arm multicenter study, treated patients aged 2 to 5 maintained or improved cognitive scores versus an untreated historical control. Patients receive corticosteroids from one day before infusion through at least eight weeks after, with warnings including thrombotic microangiopathy.

    Why it matters: First FDA-approved therapy for a rare pediatric neurodegenerative disease with no prior disease-altering treatment.

Sep 4Fri
  1. fda.gov70

    FDA Approves First Drug to Treat Alexander Disease

    The FDA has approved Zanvastro (zilganersen) injection from Ionis Pharmaceuticals for Alexander disease in pediatric and adult patients, the first treatment for this rare neurological disorder and the first to target the abnormal GFAP protein buildup that drives it. Efficacy rested on a 49-patient randomized controlled study plus a 4-patient open-label substudy in infants under 2, with treated patients aged 5 and older showing better walking speed at 61 weeks. The antisense oligonucleotide is injected into the spinal canal every three months.

    Why it matters: First-ever FDA approval for a rare neurodegenerative disease, granted to Ionis Pharmaceuticals.

Aug 29Sat
  1. fda.gov66

    FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

    The FDA approved Takeda Pharmaceuticals' Mimrylo (rusfertide) for adults with polycythemia vera whose disease is not adequately controlled by existing therapies. It is the first approved treatment for the disorder that mimics hepcidin, limiting iron available for red blood cell production. In the phase 3 VERIFY trial of 293 adults, 76.9% on Mimrylo needed no phlebotomies over 32 weeks versus 32.9% on placebo; common adverse reactions were injection site reactions and anemia. Approval followed priority review.

    Why it matters: First-in-class hepcidin mimic approved for polycythemia vera based on phase 3 VERIFY results.

Aug 28Fri
  1. fda.gov69

    FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

    The FDA has approved Priovant Therapeutics' Lisraya (brepocitinib) tablets, the first oral treatment indicated for dermatomyositis in adults. The once-daily JAK/TYK2 inhibitor was supported by a phase 3 placebo-controlled study of 241 adults, in which the 30 mg dose produced a higher average Total Improvement Score at week 52 and allowed more patients to cut corticosteroid use. It carries a boxed warning for serious infections, mortality, malignancies, cardiovascular events and thrombosis, and was granted Orphan Drug and Priority Review designations.

    Why it matters: First FDA-approved oral therapy for dermatomyositis, a rare disease with few treatment options.

Aug 20Thu
  1. fda.gov69

    FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia

    The FDA granted accelerated approval to Ultragenyx Pharmaceutical's Genglycos (pariglasgene brecaparvovec-opnr), a one-time AAV8 gene therapy and the first approved treatment for glycogen storage disease type Ia in patients aged 8 and older. In a 48-week randomized placebo-controlled study, patients achieved a statistically significant 31% mean reduction in daily cornstarch intake, the primary endpoint. The manufacturer must complete additional trials to confirm effectiveness, and the label warns of anaphylaxis, liver toxicity, adrenal insufficiency and tumorigenicity risk.

    Why it matters: FDA cleared the first therapy for glycogen storage disease type Ia under the accelerated pathway.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org